A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAG-NEGATIVE, CHRONIC HEPATITIS B: WEEK 48 EFFICACY AND SAFETY RESULTS

被引：5

作者：

Buti, M. ^{[1
]}

Gane, E. ^{[2
]}

Seto, W. K. ^{[3
]}

Chan, H. L. Y. ^{[4
]}

Chuang, W. -L. ^{[5
]}

Stepanova, T. ^{[6
]}

Hui, A. J. ^{[7
]}

Lim, Y. -S. ^{[8
]}

Mehta, R. ^{[9
]}

Janssen, H. L. A. ^{[10
,11
]}

Acharya, S. K. ^{[12
]}

Flaherty, J. F. ^{[13
]}

Massetto, B. ^{[13
]}

Cathcart, A. ^{[13
]}

Dinh, P. ^{[13
]}

Subramanian, G. M. ^{[13
]}

McHutchison, J. G. ^{[13
]}

Pan, C. ^{[14
]}

Brunetto, M. ^{[15
]}

Izumi, N. ^{[16
]}

Marcellin, P. ^{[17
]}

机构：

[1] Hosp Gen Univ Vall dHebron, Barcelona, Spain

[2] Auckland Clin Studies, Auckland, New Zealand

[3] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China

[4] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China

[5] Kaoshing Med Univ Hosp, Kaoshing, Taiwan

[6] Modern Med Clin, Moscow, Russia

[7] Alice Ho Miu Ling Nethersole Hosp, Hong Kong, Hong Kong, Peoples R China

[8] Asan Med Ctr, Seoul, South Korea

[9] Nirmal Hosp Private Ltd, Surat, India

[10] Toronto Western Hosp, Toronto, ON, Canada

[11] Erasmus MC, Rotterdam, Netherlands

[12] All India Inst Med Sci, New Delhi, India

[13] Gilead Sci, Foster City, CA USA

[14] New Discovery LLC, Flushing, NY USA

[15] Univ Hosp Pisa, Pisa, Italy

[16] Musashino Red Cross Hosp, Tokyo, Japan

[17] Hop Beaujon, Clichy, France

来源：

JOURNAL OF HEPATOLOGY | 2016年 / 64卷

关键词：

D O I：

10.1016/S0168-8278(16)01637-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

GS06

引用

页码：S135 / S136

页数：2

共 50 条

[21] TENOFOVIR ALAFENAMIDE (TAF) COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH CHRONIC HBV: WEEK 96 EFFICACY AND SAFETY RESULTS IN CHINESE PATIENTS ENROLLED IN 2 GLOBAL PHASE 3 STUDIES
Chan, Henry Lik-Yuen
Seto, Wai Kay
Fung, Scott
Hou, Jinlin
Pan, Calvin
Chuang, Wan-Long
Chang, Ting-Tsung
Hui, Aric-Josun
Chen, Chi-Yi
Tsang, Tak Yin Owen
Yang, Jenny
Flaherty, John
Gaggar, Anuj
Mo, Shuyuan
Kao, Jia-Horng
GUT, 2018, 67 : A302 - A302
[22] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS
Chan, Henry Lik Yuen
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
GUT, 2019, 68 : A142 - A143
[23] Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Buti, Maria
Gane, Edward
Seto, Wai Kay
Chan, Henry L. Y.
Chuang, Wan-Long
Stepanova, Tatjana
Hui, Aric-Josun
Lim, Young-Suk
Mehta, Rajiv
Janssen, Harry L. A.
Acharya, Subrat K.
Flaherty, John F.
Massetto, Benedetta
Cathcart, Andrea L.
Kim, Kyungpil
Gaggar, Anuj
Subramanian, G. Mani
McHutchison, John G.
Pan, Calvin Q.
Brunetto, Maurizia
Izumi, Namiki
Marcellin, Patrick
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (03) : 196 - 206
[24] Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hong, Hyeyeon
Choi, Won-Mook
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
Choi, Jonggi
CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 49 - 63
[25] THREE YEARS EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN ASIANS WITH HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B, PRELIMINARY ANALYSIS
Lee, Samuel S.
Heathcote, E. Jenny
Sievert, William
Trinh, Huy N.
Kaita, Kelly D.
Younossi, Zobair M.
George, Jacob
Shiffman, Mitchell L.
Marcellin, Patrick
Sorbel, Jeff
Anderson, Jane
Mondou, Elsa
Ouinn, Joe
Rousseau, Franck
HEPATOLOGY, 2009, 50 (04) : 538A - 538A
[26] Improved Bone and Renal Safety at 1 Year after Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Results from 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB)
Pan, Calvin Q.
Brunetto, Maurizia R.
Hui, Aric Josun
Mehta, Rajiv
Flaherty, John F.
Suri, Vithika
Wu, George
Gaggar, Anuj
Subramanian, Mani
Nishiguchi, Shuhei
Kim, Hyung J.
Gane, Edward J.
Chuang, Wan-Long
HEPATOLOGY, 2017, 66 : 482A - 482A
[27] IMPROVED BONE AND RENAL SAFETY AT 1 YEAR AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF): RESULTS FROM 2 PHASE 3 STUDIES IN HBEAG-POSITIVE AND HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Chan, Henry Lek-Yuen
Pan, Calvin
Brunetto, Maurizia
Hui, Aric Josun
Mehta, Rajiv
Flaherty, John F.
Suri, Vithika
Wu, George
Gaggar, Anuj
Subramanian, G. Mani
Nishiguchi, Shuhei
Kim, Hyung Joon
Gane, Edward
Chuang, Wan Long
GUT, 2018, 67 : A97 - A98
[28] Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics
Hsu, Yao-Chun
Wei, Mike T.
Nguyen, Mindie H.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (11) : 999 - 1008
[29] Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients
Hye Yeon Chon
Sang Hoon Ahn
Yoon Jun Kim
Jung-Hwan Yoon
Jeong-Hoon Lee
Dong Hyun Sinn
Seung Up Kim
Hepatology International, 2021, 15 : 1328 - 1336
[30] Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients
Chon, Hye Yeon
Ahn, Sang Hoon
Kim, Yoon Jun
Yoon, Jung-Hwan
Lee, Jeong-Hoon
Sinn, Dong Hyun
Kim, Seung Up
HEPATOLOGY INTERNATIONAL, 2021, 15 (06) : 1328 - 1336

← 1 2 3 4 5 →